Allergan Delays Two Late-Stage Trials

Allergan Inc. (NYSE: AGN) warned that late-stage trials of its hair loss treatment Bimatoprost Scalp and its age-related macular degeneration drug Darpin must be delayed due to disappointing mid-stage results. The stock price plummeted $14.35 to $99.20.

Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here